Blake Borgeson - 22 Aug 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Director
Issuer ticker: RXRX
Reported as of: 22 Aug 2023
Net transaction value: -$79,181
SEC form: 4
Accepted by SEC: 24 Aug 2023, 17:51:36 UTC
Prior SEC filing: 10 Aug 2023
Next SEC filing: 07 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Golightly, attorney-in-fact

Key filing fact

Blake Borgeson filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 24 Aug 2023.

Key facts

This page summarizes Blake Borgeson's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Aug 2023, 17:51.

Change

Previous filing in this sequence was filed on 10 Aug 2023.
Current net transaction value: -$79,181.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Sale

Transaction value: $79,181
Shares: -8,885
Change %: -0.12%
Price: $8.91
Shares after: 7,460,730
Date: 22 Aug 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022.

Footnote F2

The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.70 to $9.14 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.